Jason Westin, MD FACP FASCO

Professor @MDAndersonNews, Lead of Lymphoma/Myeloma Service Line, Director of Clinical Research, Section Chief of Aggressive/Indolent Lymphomas, Opinions mine

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

I am so honored to receive the @ASCO Advocate of the Year award. Engaging with advocacy is such an important way to support our patients. #ASCOAdvocacySummit

[ASCO @ASCO]

“If we're not advocating…fighting against #drugshortages & for NCI funding & the CONNECT for Health Act, others are advocating the other direction...What you're doing here really matters,” Advocate of the Year @lymphoma_doc. Congrats! https://t.co/UiVKrQNLXc #ASCOAdvocacySummit

[ASCO @ASCO]

Prior authorization delays harm people w cancer. The #SeniorsAct, is a bipartisan bill that would help #FixPriorAuth in Medicare Advantage and improve pt care. Congress needs to act NOW.

Tell your lawmakers to pass the Seniors Act: https://t.co/amgEdcKSGD
#ASCOAdvocacy

[AACR @AACR]

New Targeted Therapeutic Strategies in Lymphoma:
Kerry Rogers, Mark Roschewski, and Jason Westin discussed this topic in a plenary session at the AACR Conference on Advances in Malignant Lymphoma.
#AACRlymphoma26 @RoschewskiMD @Lymphoma_Doc

[ASCO @ASCO]

➡️Head on over to S100a NOW! ASCO Voices session has started. Called “one of the most compelling sessions at the Mtg.” Get inspired by the oncology community as 5 individuals share their personal narratives and calls to action. 🤩 #ASCO26

[Peter WT Pisters, MD @ppisters]

Thrilled to see @UTMDAnderson receive @FDA IND clearance to begin a Phase 1 clinical trial for a novel CD94-targeted CAR T cell therapy. This scientific breakthrough represents hope for patients facing challenging diseases without existing successful therapy options. #EndCancer

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial [Dec 29, 2012] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth #NCT00352846

[ASCO @ASCO]

During #ASCOAdvocacySummit we asked lawmakers to prioritize robust funding for @NIH, @theNCI, & @ARPA_H in fiscal year 2027 to support research, maintain the workforce, & drive breakthroughs that improve treatment options. Add your voice ➡️ https://t.co/AIlROM6f2r

[Ruiling Yuan @yuan_ruiling]

Honored to be named ASCO 2025 Advocate of the Year.

Grateful to @ASCO & the Advocacy team, Team SC, and especially @JasmineKamboj for mentorship that changed my path.

This is for my patients.

Advocacy in oncology isn’t optional, it’s essential.

#ASCOAdvocacy #RuralOncology

[ASCO @ASCO]

The 2026 #ASCOAdvocacySummit and online Week of Action start today! Join us in urging Congress to:
- Prioritize federal research funding
- #FixPriorAuth
- Permanently extend Medicare telehealth flexibilities

Learn more: https://t.co/xM2QQZVxno

[ASCO @ASCO]

Don’t get left behind! ⏰ Early registration for #ASCO26 closes soon. Secure your discounted spot at The Place to Be for the global oncology community by registering before April 22 at 11:59 PM (ET). We can't wait to see you! https://t.co/VHjZqD4AoT

[Journal of Clinical Oncology @JCO_ASCO]

JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance @ASCO’s flagship & highly cited publication.

Interest forms due March 9. Apply: https://t.co/pdMRC3fQ9c

[VJHemOnc @VJHemOnc]

Missed our Post-ASH 2025 #Lymphoma highlights webinar? 💻 🩸 Catch up below! 👇

Chair: @Lymphoma_Doc | Moderators: @gloria_iacoboni & Laurie Sehn

Covering:
📌 Session 1: Recent progress with chemotherapy treatment and outcomes
📌 Session 2: Advances with CAR T-cell therapies
📌 Session 3: Latest with bispecifics
📌 Session 4: Developments with additional immunotherapies and targeted therapies
+ Panel discussion answering YOUR questions 💬

Explore the #Lymphoma highlights 👉 https://t.co/nImWXdrpCt

[ASCO @ASCO]

📢 Big update! @NealMeropol joins us as #TAPUR Study PI on 7/1. His leadership will help us advance this landmark study to deliver on the promise of personalized medicine.

👏 Gratitude to @rschilsky for his visionary leadership as inaugural PI

https://t.co/u221KIrZoL

[Rep. Jake Auchincloss 🟧 @RepAuchincloss]

Commissioner @DrMakaryFDA must testify before the Health subcommittee on his terrible leadership of the Food & Drug Administration. Trust in safety & efficacy standards is collapsing.

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

@doctorpemm @JCO_ASCO @Daver_Leukemia @MDAndersonNews @lane_andy @mtmdphd @montypal @VivekSubbiah @KMirza @VJHemOnc @ASCO @mpdrc @NitinJainMD Congrats!!! Very impressive manuscript and hopefully another advance for patients with BPDCN

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Delighted to share our brand new paper 📝 now online @JCO_ASCO | Final results of our Ph 1/2 #Pivekimab Sunirine (#CD123-targeted ADC) in patients with #BPDCN | https://t.co/f9Zfd3qyAq | led by @doctorpemm & @Daver_Leukemia | @MDAndersonNews #endcancer #BPDCN #leusm

[Sean @SeanODowd15]

If you read the other AI article, you need to read this one

Ex-OpenAI employees wrote it a year ago, and they predicted we’ll know how AI ends by 2027

Thus far, they’ve been remarkably accurate in their predictions

https://t.co/UwT4jDLO2T

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Check out this awesome upcoming event for Practical tips post- #MarchDay seminar hosted Aditi Pemmaraju & team .@homesforhealers ! #meded 🏡 🩺 🙌

[Yan Leyfman, MD @YLeyfman]

Promising data from Rapcaptogene for DLBCL using the T charge platform at Tandem 2026 from Global Lymphoma Leader Dr. Jason Westin, MD MS FASCO of MD Anderson Cancer Center.

#tandem26 #tandem2026 #celltherapy #cartcells

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

@YLeyfman @MDAndersonNews @NovartisCancer @ASTCT @CIBMTR Thanks @YLeyfman!